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Phthalates are high-production-volume chemi-
cals. Some phthalates make plastics pliable and 
may be used in vinyl flooring, medical devices, 
wall coverings, toys, and food containers. Other 
phthalates are often found in personal care 
products (e.g., cosmetics, lotions, perfumes) 
and in the coatings of some medications (David 
et al. 2001; Koch and Calafat 2009; Schettler 
2006). The ubiquitous use of phthalates results 
in widespread human exposure [Centers for 
Disease Control and Prevention (CDC) 2010]. 
In humans, phthalates are rapidly metabolized 
to their corresponding hydrolytic monoesters, 
which can be further transformed to oxidative 
products, conjugated, and eliminated (Koch 
and Calafat 2009).
Urinary phthalate metabolite concentra-
tions represent an integrative measure of expo-
sure to phthalates from multiple sources and 
routes. Therefore, phthalate metabolites have 
been used extensively as exposure biomark-
ers (Koch and Calafat 2009). However, per-
sonal exposure to phthalates is likely to vary 
over time as a result of changes in the use of 
personal care products, diet, or daily activi-
ties. Although the urinary concentrations of 
phthalate metabolites can be used to accurately 
measure the exposure of a person at a single 
point in time, because of the short elimina-
tion half-life (t1/2) of phthalates (i.e., a few 
hours) (Koch and Calafat 2009), determining 
exposure over weeks or months may require 
multiple measurements. Therefore, informa-
tion on the temporal variability of urinary con-
centrations of phthalate metabolites is needed 
to optimize the design of exposure assessment 
in epidemiologic studies.
Several studies have shown that the concen-
trations of phthalate metabolites in a single urine 
sample can provide a reliable ranking to classify 
a person’s exposure to phthalates for up to sev-
eral months, although some metabolites display 
more temporal variability than others (Adibi 
et al. 2008; Fromme et al. 2007; Hauser et al. 
2004; Hoppin et al. 2002; Peck et al. 2010; 
Teitelbaum et al. 2008). These reports suggest 
that urinary concentrations of phthalate metab-
olites in serial samples vary over periods of time. 
However, to date, no studies have addressed 
either intraday variability or the variability of 
spot samples, first morning voids, and 24-hr 
collections obtained from the same person.
We report the variability over a period 
of 1 week in phthalate exposure by using 
the metabolites of two example phthalates, 
diethyl phthalate (DEP) and di(2-ethylhexyl) 
phthalate (DEHP). We chose these phthalates 
because of their relatively short elimination 
t1/2 but differing main exposure pathways and 
metabolism. The main exposure pathway to 
DEP is dermal absorption from the use of 
personal care products that contain DEP and, 
to a lesser extent, ingestion and inhalation 
(Api 2001). By contrast, ingestion of food 
is the likeliest source of exposure to DEHP 
(Kavlock et al. 2006). DEP is a low-  molecular-
weight phthalate metabolized mainly to its 
hydrolytic monoester, monoethyl phthalate 
(MEP), before urinary excretion. Conversely, 
DEHP is a high-molecular-weight phthalate 
that is also first hydrolyzed to its hydrolytic 
monoester but undergoes further metabolism, 
which results in numerous products, includ-
ing the oxidative metabolite mono(2-ethyl-5-
hydroxyhexyl) phthalate (MEHHP).
We present the variability of urinary con-
centrations of MEP and MEHHP in eight 
adults over 7 consecutive days. This study 
provides data to help elucidate patterns of 
within- and between-person and of within- 
and between-day variability. Furthermore, 
this study is the first to provide information 
of the variance apportionment of the concen-
trations of phthalate metabolites by person, 
day, and time of day for spot, first morning, 
and 24-hr void urine samples collected from 
the same person.
Methods
Study design. In 2005, eight adults were 
recruited to participate in a study designed 
to examine the temporal variability in the 
urinary concentrations of several polycyclic 
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Ba c k g r o u n d: Phthalates are metabolized and eliminated in urine within hours after exposure. 
Several reports suggest that concentrations of phthalate metabolites in a spot urine sample can pro-
vide a reliable estimation of exposure to phthalates for up to several months.
oBjectives: We examined inter- and intraperson and inter- and intraday variability in the concen-
trations of monoethyl phthalate (MEP), the major metabolite of diethyl phthalate, commonly used 
in personal care products, and mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), a metabolite 
of di(2-ethylhexyl) phthalate (DEHP), a polyvinyl chloride plasticizer of which diet is the principal 
exposure source, among eight adults who collected all urine voids (average, 7.6 samples/person/day) 
for 1 week.
Me t h o d s : We analyzed the urine samples using online solid-phase extraction coupled to isotope 
dilution–high-performance liquid chromatography–tandem mass spectrometry.
re s u l t s: Regardless of the type of void (spot, first morning, 24-hr collection), for MEP, interperson 
variability in concentrations accounted for > 75% of the total variance. By contrast, for MEHHP, 
within-person variability was the main contributor (69–83%) of the total variance. Furthermore, we 
observed considerable intraday variability in the concentrations of spot samples for MEHHP (51%) 
and MEP (21%).
co n c l u s i o n s: MEP and MEHHP urinary concentrations varied considerably during 1 week, but 
the main contributors to the total variance differed (interday variability, MEHHP; interperson vari-
ability, MEP) regardless of the sampling strategy (spot, first morning, 24-hr collection). The nature 
of the exposure (diet vs. other lifestyle factors) and timing of urine sampling to evaluate exposure 
to phthalates should be considered. For DEHP and phthalates to which people are mostly exposed 
through diet, collecting 24-hr voids for only 1 day may not be advantageous compared with mul-
tiple spot collections. When collecting multiple spot urine samples, changing the time of collection 
may provide the most complete approach to assess exposure to diverse phthalates.
key w o r d s : biomonitoring, DEHP, DEP, exposure, human, phthalates, urine, variability. Environ 
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aromatic hydrocarbon (PAH) metabolites (Li 
et al. 2010). The study volunteers (four males 
and four females) were healthy, nonsmoking 
CDC employees living in the metropolitan 
Atlanta, Georgia, area, ranging in age from 
25 to 59 years, with no documented occu-
pational exposure to PAH or phthalates [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.1002231)]. The institutional review board 
of CDC approved this study, and all partici-
pants provided written informed consent.
During a 1-week study period in October–
November 2005 [see Supplemental Material, 
Table 1 (doi:10.1289/ehp.1002231)], each 
person, while engaged in his or her nor-
mal daily activities, collected all urine voids 
throughout the day and night in a com-
mercial nonvinyl plastic specimen collection 
container. After collection, the participants 
recorded the urine volume and time of the 
void, decanted an approximately 50-mL ali-
quot of the urine to a prelabeled, sterile, 4-oz 
polypropylene/polyethylene urine collection 
cup, stored the cup in an ice cooler containing 
frozen ice packs, and discarded the remainder 
of the urine. The urine samples were retrieved 
from each participant daily (or after the week-
end), aliquoted into polypropylene cryo-
vials or glass jars, and frozen at –70°C until 
analysis. Participants also noted day and time 
of missed collections and recorded detailed 
information on their diet, driving, and out-
door activities during the week of the study.
Phthalate metabolite measures. The 
approach for determining the urinary con-
centrations of phthalate metabolites has been 
described in detail (Kato et al. 2005). Briefly, 
the analytical method involved enzymatic 
deconjugation of the phthalate metabolites 
from the glucuronidated form, followed by 
online solid-phase extraction, separation with 
high-performance liquid chromatography, 
and detection and quantitation by isotope-di-
lution tandem mass spectrometry. Analytical 
standards, quality control (QC) materials 
(prepared from spiked pooled urine), and 
reagent blank samples were included in each 
batch along with study samples. The QC con-
centrations—averaged to obtain one measure-
ment of high-concentration QC and one of 
low-concentration QC for each batch—were 
evaluated by using standard statistical prob-
ability rules (Caudill et al. 2008). With the 
analytical method used, we can obtain data 
for up to 16 phthalate metabolites. However, 
for the statistical analysis, we considered only 
MEP and MEHHP. Creatinine, used to cor-
rect for the dilution of the urine, was meas-
ured at CDC by using an enzymatic reaction 
on a Roche Hitachi 912 chemistry analyzer 
(Hitachi, Pleasanton, California).
Statistical analysis. Statistical analyses were 
carried out using SAS version 9.2 (SAS Institute 
Inc., Cary, NC). Concentrations below the 
limit of detection (LOD) (MEP: 0.4 μg/L; 
MEHHP: 0.32 μg/L) were replaced with the 
LOD divided by the square root of 2 (Hornung 
and Reed 1990). The urinary metabolite con-
centrations followed a log-normal distribution; 
therefore, all data were log10-transformed before 
statistical analysis. First morning voids were 
defined as the first sample collected from each 
person at or after 0500 hours each day. A simu-
lated 24-hr void concentration was calculated as 
the volume-weighted average of all specimens 
collected by an individual during a 24-hr period 
starting at midnight.
To assess the impact of creatinine adjust-
ment to the total variance when exposure is 
categorized from the urinary concentrations of 
spot samples, we built three different models: 
a) without creatinine correction for urinary 
dilution (unadjusted); b) using creatinine-
  corrected concentrations (creatinine corrected); 
and c) including creatinine as a model covariate 
(creatinine adjusted). We ranked these models 
based on their Akaike information criterion 
(AIC) values (the lower the AIC, the better 
the model). To assess the temporal variabil-
ity in phthalate concentrations, we calculated 
intra  class correlation coefficients (ICCs) for 
the three collections (spot, first morning, and 
simulated 24-hr voids). The ICC indicates the 
temporal reproducibility of repeated measures 
and is computed by dividing the estimate of 
the between-person variance by the estimated 
total variance. ICC ranges from 0 (poor reli-
ability) to 1 (high reliability). To generate the 
variance component in the calculation of the 
ICCs, we used the three-level unconditional 
(intercept only) random-effect model. Level 1 
is the time (i), which is nested within the day 
(level 2, j = 7), which is nested within the 
participants (level 3, k = 8). The only fixed 
effect was the grand mean of the intercept. The 
model equation was Yijk = (Y000) + (V00k + U0jk 
+ γijk), where Yijk is the log10 (metabolite con-
centration) for participant k on day j at time i. 
Y000 is the grand mean (intercept), and V00k, 
U0jk, and γijk are the random errors for level 3, 
level 2, and level 1 residual, respectively.
We categorized the time of sample collec-
tion as morning (after midnight–1159 hours), 
afternoon (1200–1800 hours), and evening 
(1801–2359 hours), and calculated the geo-
metric mean (GM) concentration for each 
collection time. We examined the association 
between time of sample collection and the uri-
nary concentrations in a one-way mixed model.
Results
We analyzed a total of 427 urine samples 
collected within the 7-day period from eight 
adult participants [see Supplemental Material, 
Table 1 (doi:10.1289/ehp.1002231)]. 
MEP was detected in all except one sample. 
MEHHP was detected in every sample col-
lected from four of the eight participants; for 
the remaining four persons, MEHHP detec-
tion frequency ranged from 95 to 98%. The 
GM, median, and interquartile concentrations 
from all samples, first morning voids, and 
simulated 24-hr voids are shown in Table 1.
Throughout the study week, urinary 
concentrations varied by up to two (MEP) 
and three (MEHHP) orders of magnitude. 
Of interest, concentrations of MEP (Table 2, 
Figure 1) and MEHHP (Table 3, Figure 2) for 
each person varied considerably throughout the 
day. The average intraperson coefficient of vari-
ation (CV) of creatinine-corrected MEP con-
centrations in the spot urine samples collected 
throughout the week was 92% and ranged 
from 62% (participant P1) to 157% (partici-
pant P6). Similarly, for creatinine-  corrected 
MEHHP concentrations, intraperson CVs 
averaged 161% and ranged from 74% (partici-
pant P5) to 263% (participant P2).
Furthermore, when the urinary con-
centrations of each study participant were 
Table 1. Urinary concentrations of MEP and MEHHP for all spot urine samples, first morning voids, and reconstructed 24-hr collections from all eight 
participants.a
Urinary concentrations [uncorrected (µg/L) and creatinine corrected (µg/g)]
All spot samples (n = 427) First morning void (n = 56) Reconstructed 24-hr collection (n = 56)
Phthalate metabolite GM Median Interquartile GM Median Interquartile GM Median Interquartile
MEP
µg/L 61.7 50.8 20–199 103 69 20.1–309 97.1 68.5 30.1–411
µg/g creatinine 105 75 32–280 86.7 45 30.3–161 136 97.1 41–409
MEHHP
µg/L 22.2 21.3 6.7–71.6 40.2 36.5 22.9–73.9 38.8 28.4 16.5–115
µg/g creatinine 37.6 29.8 15.5–76.2 33.6 28.05 18.4–55.4 55.9 44.7 21.8–163
aFor comparison purposes, the National Health and Nutrition Examination Survey (NHANES) 2005–2006 urinary concentrations (GM, median, 75th percentile) in micrograms per liter for 
adults are MEP (173, 168, 453) and MEHHP (23.4, 21.4, 48.6) (CDC 2010).Preau et al.
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plotted over the week, participants P6 and 
P8 showed a pronounced cyclic pattern of 
MEP measurements for every day of the 
week. Participant P4 also had a daily MEP 
pattern, albeit only for 4–5 days, but for 
the other participants (P1, P2, P3, P5, P7; 
Figure 1), a clear visual pattern was not as 
evident. A less-pronounced MEHHP daily 
cyclic pattern was observed only for partici-
pants P1 and P3 (Figure 2). We observed 
similar patterns, although with the differences 
somewhat less pronounced for each partici-
pant, for the log10-transformed concentra-
tions [see Supplemental Material, Figures 1–2 
(doi:10.1289/ehp.1002231)].
In Table 4, we present the variance compo-
nents when the MEP and MEHHP concentra-
tions of the spot urine samples are included 
as a) unadjusted (i.e., in micrograms per liter 
without accounting for dilution), b) creatinine 
corrected (i.e., in micrograms per gram creati-
nine accounting for dilution), or c) creatinine 
adjusted (by including creatinine as a model 
covariate). Independent of the dilution treat-
ment, for MEP, the between-person variance 
contributed 64–77% of the total variance. By 
contrast, for MEHHP, total within-person 
variance (between days + within days) was 
predominant, accounting for approximately 
80% of the total variance. However, for both 
phthalate metabolites, both the creatinine-
  corrected and creatinine-adjusted models 
yielded almost identical AIC values that, in 
turn, were much smaller than the AIC val-
ues obtained from models of the unadjusted 
concentrations. These results suggest that dif-
ferences in urine dilution explained some of 
the variance in the metabolite concentrations, 
because the model fits improved when we 
accounted for dilution by correcting or adjust-
ing for creatinine concentration. Therefore, 
for all subsequent variance calculations, we 
used the creatinine-corrected concentrations, 
because the simulated 24-hr voids data cannot 
be creatinine adjusted.
MEP is the hydrolytic and primary 
metabolite of DEP, whereas MEHHP is an 
oxidative metabolite of DEHP; MEHHP 
elimination t1/2 is about 3–4 times longer than 
that of MEP. To explore whether some of the 
observed differences in the variance compo-
nents are related to differences in elimination 
t1/2 of MEP and MEHHP, we calculated the 
inter- and within-person variability for the 
hydrolytic metabolite of DEHP, mono(2-
ethylhexyl) phthalate (MEHP), which has 
a t1/2 comparable with that of MEP. The 
MEHP and MEHHP results were similar [see 
Supplemental Material, Table 2 (doi:10.1289/
ehp.1002231)].
The contributions to the total vari-
ance of the creatinine-corrected concentra-
tions between and within persons observed 
for all types of collections for the study week 
are shown in Table 5. The ICCs of between-
person concentrations were 0.25 (MEHHP) 
and 0.91 (MEP) for first morning voids, 0.17 
(MEHHP) and 0.77 (MEP) for spot samples, 
and 0.31 (MEHHP) and 0.94 (MEP) for sim-
ulated 24-hr voids. For MEP, the between-
person variance (ranging from 77% to 94%) 
was much higher than the total within-
  person variance (between days + within days) 
(6–23%). Conversely, for MEHHP, the total 
within-person variance contribution (69–83%) 
was higher than the between-person variance 
contribution (17–31%). Of interest, for both 
analytes for all the spot samples collected, 
the within-day variance was higher than the 
between-day variance contribution for each 
participant. For the spot samples, 51% (for 
MEHHP) and 21% (for MEP) of the variabil-
ity was explained by within-day variation in 
individuals, rather than by variation between 
Table 2. Mean (± SD) urinary concentrations and variability of MEP for each study participant.a
Mean MEP (µg/g creatinine)
Spot collections (including first morning void) Days 1–7
Participant Monday Tuesday Wednesday Thursday Friday Saturday Sunday Spot samples First morning void 24-hr
P1 20.2 ± 7.1 33.1 ± 18.4 20.4 ± 15.9 13.0 ± 8.4 16.0 ± 11.3 23.2 ± 14.7 21.7 ± 6.5 20.6 ± 12.9 18.6 ± 5.1 21.3 ± 6.2
P2 160.7 ± 104.5 187.6 ± 110.2 97.7 ± 30.7 107.5 ± 52.7 220.2 ± 96.3 161.8 ± 111.6 87.5 ± 60.8 151.8 ± 95.2 93.5 ± 54.4 142.4 ± 53.1
P3 30.9 ± 14.9 67.4 ± 66.3 35.6 ± 16.0 36.3 ± 16.8 88.2 ± 60.1 28.0 ± 7.5 34.6 ± 21.1 45.3 ± 39.5 33.0 ± 7.4 39.6 ± 18.5
P4 1,641 ± 952 1,545 ± 1,317 2,980 ± 3,166 1,730 ± 1,136 2,631 ± 1,807 2,134 ± 1,478 3,174 ± 2,349 2,391 ± 2,065 4,848 ± 3,092 2,701 ± 1,283
P5 53.9 ± 14.1 101.4 ± 36.4 74.6 ± 55.3 41.6 ± 20.8 101.6 ± 118.4 53.6 ± 62.2 63.2 ± 47.6 69.3 ± 62.7 41.2 ± 25.2 60.4 ± 21.5
P6 305.8 ± 264.6 242.8 ± 217.2 165.6 ± 208.3 992.5 ± 1232.3 199.8 ± 165.6 242.9 ± 285.7 203.0 ± 108.4 341.1 ± 533.9 79.8 ± 41.4 334.7 ± 298.1
P7 49.4 ± 59.2 79.1 ± 64.7 102.7 ± 107.5 48.7 ± 21.9 41.3 ± 19.4 82.6 ± 73.4 56.5 ± 43.9 66.1 ± 62.1 35.4 ± 16.7 58.6 ± 20.4
P8 976.9 ± 892.4 736.1 ± 610.5 495.5 ± 345.6 363.9 ± 379.6 543.9 ± 445.3 364.9 ± 345.0 430.1 ± 413.6 586.1 ± 555.7 210.0 ± 44.9 554.5 ± 201.8
aThe average intraperson CV of concentrations in the spot urine samples collected throughout the week was 92% and ranged from 62% (P1) to 157% (P6).
Figure 1. Creatinine-corrected concentrations of MEP (µg/g creatinine) for all study participants (P1–P8) during 1 week.
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participants or between days in individuals. 
To further explore the potential influence of 
the time of collection on within-day variabil-
ity, we categorized the spot samples as morn-
ing, afternoon, and evening. For MEP, the 
GM concentrations of samples collected in the 
morning (73 μg/L) and afternoon (72 μg/L) 
were significantly higher (p < 0.01) than in 
those collected in the evening (52.8 μg/L). By 
contrast, for MEHHP, the GM concentration 
of samples collected in the evening (33.2 μg/L) 
was significantly higher (p < 0.01) than in 
samples collected in the morning (18.7 μg/L) 
or in the afternoon (18.1 μg/L).
Discussion
As expected from the ubiquitous use of 
phthalates in modern societies, our data sug-
gest widespread human exposure among this 
adult study population. The high detection 
frequency and concentrations were within 
the ranges reported for the adult U.S. general 
population from the National Health and 
Nutrition Examination Survey (NHANES) 
2005–2006 (CDC 2010).
Six previous studies have evaluated the 
temporal variability of phthalate metabo-
lites in various populations over periods 
ranging from days to months (Adibi et al. 
2008; Fromme et al. 2007; Hauser et al. 
2004; Hoppin et al. 2002; Peck et al. 2010; 
Teitelbaum et al. 2008). In three of these 
studies, researchers assessed the agreement of 
phthalate metabolite concentrations by using 
first morning urine samples collected from 46 
African-American women on 2 consecutive 
days (Hoppin et al. 2002), from 50 German 
men and women 14–60 years of age during 
8 consecutive days (Fromme et al. 2007), and 
from 25 Hmong women who provided up 
to three samples over approximately 30 days 
(Peck et al. 2010). In the other studies, 
researchers evaluated the variability of phtha-
late metabolite concentrations in multiple spot 
urine samples collected from 28 Dominican 
and African-American women who provided 
Table 3. Mean (± SD) urinary concentrations and variability of MEHHP for each study participant.a
Mean MEHHP (µg/g creatinine)
Spot collections (including first morning void) Days 1–7
Participant Monday Tuesday Wednesday Thursday Friday Saturday Sunday Spot samples First morning void 24-hr
P1 324.0 ± 296.1 163.4 ± 85.2 130.7 ± 162.2 373.2 ± 344.3 55.5 ± 54.3 24.4 ± 13.6 39.0 ± 52.6 158.0 ± 224.4 81.1 ± 56.7 139.9 ± 96.5
P2 26.6 ± 10.0 635.0 ± 730.9 67.6 ± 24.5 40.4 ± 26.6 33.8 ± 20.4 28.9 ± 12.6 126.5 ± 147.7 125.4 ± 329.8 47.7 ± 32.5 129.8 ± 139.7
P3 26.9 ± 19.9 273.4 ± 356.4 215.1 ± 235.6 473.5 ± 692.7 343.8 ± 415.3 66.5 ± 78.8 137.4 ± 123.1 218.5 ± 265.5 88.3 ± 116.7 182.2 ± 119.8
P4 16.5 ± 8.0 23.7 ± 16.6 20.1 ± 10.1 20.5 ± 8.6 18.7 ± 13.2 12.3 ± 6.4 136.5 ± 124.3 40.3 ± 68.9 15.2 ± 3.4 31.1 ± 32.9
P5 14.7 ± 5.9 12.9 ± 13.2 34.4 ± 20.3 25.2 ± 15.5 14.2 ± 10.8 18.5 ± 6.3 15.3 ± 12.9 19.0 ± 14.1 34.1 ± 9.3 24.0 ± 6.1
P6 95.7 ± 67.9 40.5 ± 14.0 33.5 ± 19.9 20.9 ± 6.9 19.8 ± 7.5 10.8 ± 6.2 25.3 ± 16.5 35.8 ± 37.1 30.1 ± 17.8 34.2 ± 24.0
P7 109.4 ± 118.0 26.7 ± 13.7 19.0 ± 5.4 19.1 ± 18.3 706.3 ± 603.4 107.0 ± 149.9 30.4 ± 29.8 109.0 ± 244.1 22.7 ± 8.2 143.6 ± 225.3
P8 8.3 ± 5.3 122.6 ± 131.6 337.8 ± 328.6 188.8 ± 137.0 243.7 ± 207.6 73.1 ± 61.4 16.7 ± 6.5 133.0 ± 187.2 60.5 ± 52.1 123.2 ± 105.0
aThe average intraperson CV of concentrations in the spot urine samples collected throughout the week was 161% and ranged from 74% (P5) to 263% (P2).
Figure 2. Creatinine-corrected concentrations of MEHHP (µg/g creatinine) for all study participants (P1–P8) during 1 week.
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Table 4. Effect of creatinine correction in the variance apportionment for the urinary concentrations of 
MEP and MEHHP in spot samples collected from eight persons over a period of 7 days.
Creatinine unadjusted Creatinine corrected Creatinine as a covariate
Variance 
component
Percentage of 
total variance
Variance 
component
Percentage of 
total variance
Variance 
component
Percentage of 
total variance
MEP
AIC 543.7   342.6   335.4
Between persons 0.35 64 0.41 77 0.39 76
Within person, 
between days
0.01 2 0.01 2 0.01 2
Within person, 
within day
0.19 35 0.11 21 0.11 22
MEHHP
AIC 820.3   579   574.5
Between persons 0.1 18 0.06 17 0.06 17
Within person, 
between days
0.13 24 0.11 32 0.11 32
Within person, 
within day
0.32 58 0.17 51 0.17 51Preau et al.
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two to four samples over 6 weeks during their 
last trimester of pregnancy (Adibi et al. 2008), 
from 11 men who provided nine samples each 
over 3 months (Hauser et al. 2004), and from 
35 Hispanic and African-American children 
6–10 years of age who collected two to seven 
samples over 6 months (Teitelbaum et al. 
2008). Except for one study (Fromme et al. 
2007), all others assessed the variability of 
MEP, although two older reports (Hauser 
et al. 2004; Hoppin et al. 2002) did not assess 
the variability of MEHHP and other DEHP 
oxidative metabolites.
In agreement with the ICCs reported pre-
viously for MEHHP urinary concentrations of 
first morning voids over 8 days to ~ 1 month 
(Fromme et al. 2007; Peck et al. 2010) and 
of spot samples collected within 6 weeks to 
~ 6 months (Adibi et al. 2008; Teitelbaum 
et al. 2008), we found that between-person 
MEHHP creatinine-corrected concentrations 
for our study population varied considerably 
over 7 consecutive days (ICC = 0.25 for first 
morning voids; ICC = 0.17 for spot samples). 
By contrast, we found a low variability of 
between-person creatinine-corrected concen-
trations of MEP during the same time period 
(ICC = 0.91 for first morning voids; ICC = 
0.77 for spot samples). Other studies have also 
reported moderate (ICC = ~ 0.6) reproduc-
ibility in MEP urinary measures (Hauser et al. 
2004; Hoppin et al. 2002; Peck et al. 2010).
In this study, the largest contribution of 
the total variance of MEP urinary concentra-
tions in spot samples was the between-person 
variability (77%). Throughout the day, the 
average person’s variance was also consider-
able (21%), but the average person’s between-
day variance was rather low (2%). Similarly, 
the largest percentage of total variance in 
MEP concentrations from first morning and 
24-hr voids was also the variation between 
each person (91% and 94%, respectively).
DEP exposure is largely associated 
with the use of personal care products (Api 
2001; Berman et al. 2009; Duty et al. 2005; 
Houlihan et al. 2002; Hubinger and Havery 
2006; Koo and Lee 2004; Sathyanarayana 
et al. 2008; Schettler 2006). The large 
between-person variability of MEP urinary 
concentrations we observed among this group 
of adults is likely related to the fact that dif-
ferent people use different types and com-
binations of personal care products. On the 
other hand, the fact that the persons exam-
ined had a large variation in MEP urinary 
concentrations throughout a given day, but 
very small variation between days, may be 
related to their regular use of personal care 
products. We speculate that people typically 
use the same personal care products at similar 
times in their daily routines and that indi-
viduals also tend to apply personal care prod-
ucts in similar amounts and frequency every 
day. Furthermore, the regular use of personal 
care products at similar times every day and 
the short DEP elimination t1/2 could result 
in MEP being excreted every day at similarly 
spaced times. This behavioral use of DEP-
containing personal care products may also 
explain the appearance of a cyclic pattern in 
MEP urinary concentration in the persons 
with the largest concentrations of MEP dur-
ing the study week. Of interest, the cyclic 
pattern was particularly evident during the 
work week but seemed to change for many 
participants over the weekend.
Unlike MEP, the largest variation of 
MEHHP urinary concentrations in spot sam-
ples was related to the variation of each person 
throughout the day (51%). The within-person 
variability between days was also considerable 
(32%) and about twice the variation attrib-
uted to differences between persons (17%). 
Likewise, the largest contributor to the total 
variance of MEHHP concentrations in first 
morning and 24-hr urine voids was individual 
variability from day to day (75% and 69%, 
respectively). We obtained similar results for 
MEHP, the DEHP hydrolytic metabolite, 
even though MEHHP elimination t1/2 is 3–4 
times longer than of MEHP, suggesting that 
the main factors affecting the observed vari-
ance for MEHHP and MEHP concentrations 
are similar. Exposure to DEHP, the MEHHP 
precursor in the body, is largely associated 
with the consumption of food (Kavlock et al. 
2006). Not only do diets vary from person to 
person, but an individual’s food consumption 
typically changes from day to day. Consistent 
with this, we did not observe clear daily pat-
terns in MEHHP urinary concentrations for 
most participants.
Our findings also suggest that, regardless 
of the type of sample collected (i.e., spot, first 
morning, and 24-hr voids), when diet is the 
likely main source of exposure (i.e., DEHP), 
interday variability is a main contributor to 
the total variance. By contrast, when routine 
daily use of a product is the main exposure 
source (i.e., DEP), interperson variability 
appears to be the main contributor to the 
total variance. However, age will have a strong 
impact in relation to exposure to environmen-
tal chemicals, including phthalates, because 
behavior and diet, among other factors, are 
likely contributors to exposure to these com-
pounds. For example, for young children, 
particularly infants, diet may not be as diver-
sified as it is for adults. The extent and pat-
terns of use of personal care products among 
children and adults are also expected to differ. 
Therefore, some of the findings we report for 
this group of adults may not apply to chil-
dren and other age groups. Furthermore, the 
number of study participants examined was 
rather small, although the reported MEP and 
MEHHP urinary concentrations fell within 
the NHANES reference ranges. For the above 
reasons, we recommend caution in the gener-
alization of our findings to other populations.
Twenty-four hour urine specimens do 
not require a correction for the urine dilu-
tion, which is important because no consen-
sus exists on the best method for conducting 
such adjustment (Adibi et al. 2008; Barr et al. 
2005; Pearson et al. 2009). On the other 
hand, our findings suggest that collecting 
24-hr samples for only 1 day could benefit 
studies designed to evaluate compounds to 
which people are mostly exposed through 
routine use of personal care products. 
Unfortunately, for many chemicals, the con-
tribution to the total exposure from all poten-
tial sources is either variable or unknown. In 
addition, epidemiologic studies often evaluate 
exposure to a wide range of compounds (and 
their corresponding exposure sources). As a 
result, collecting 24-hr voids may not nec-
essarily eliminate the potential for exposure 
Table 5. Variance apportionment for the creatinine-corrected concentrations of MEP and MEHHP in urine samples collected from eight persons over a 1-week 
period.
Spot samples (n = 247) First morning void (n = 56) Reconstructed 24-hr voids (n = 56)
Variance parameter
Variance component 
(95% CI)
Percentage of 
total variancea
Variance component 
(95% CI)
Percentage of 
total variancea
Variance component 
(95% CI)
Percentage of 
total variance a
MEP
Between persons 0.41 (0.18–1.71) 77 0.53 (0.23–2.26) 91 0.47 (0.2–1.97) 94
Within person, between days 0.01 (0.003–0.04) 2 0.051 (0.04–0.08) 9 0.029 (0.02–0.045) 6
Within person, within day 0.11 (0.10–0.13) 21
MEHHP
Between persons 0.06 (0.02–0.48) 17 0.03 (0.01–0.33) 25 0.072 (0.026–0.59) 31
Within person, between days 0.11 (0.07–0.20) 32 0.09 (0.06–0.14) 75 0.16 (0.11–0.25) 69
Within person, within day 0.17 (0.15–0.20) 51
aThe ICC is the between-person percentage of total variance divided by 100.Variability in urinary phthalate metabolite levels
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misclassification, at least for some of the 
compounds examined. Therefore, when the 
population is sufficiently large, the spot-sam-
pling approach may provide enough statisti-
cal power to adequately categorize exposure, 
particularly when samples are collected on 
multiple days.
One of the most important findings of this 
work is to show that, for a given person, the 
urinary concentrations of phthalate metabo-
lites can change considerably throughout the 
day. Others have observed similar intraday 
variability in the urinary concentrations of 
other nonpersistent chemicals, such as PAH 
metabolites (Li et al. 2010). More important, 
even for the two metabolites we evaluated, 
the intraday changes went in opposite direc-
tions. For example, we found that the lowest 
MEP urinary concentrations, but the high-
est MEHHP concentrations, occurred in the 
evening. These findings suggest that sampling 
strategy should be one critical factor when 
designing epidemiologic studies that include 
biomonitoring measures of urine specimens. 
Very often these specimens are analyzed for 
more than one class of environmental chemi-
cals. Therefore, when multiple collections of 
spot urine samples over a period of days to 
weeks or months are logistically and economi-
cally possible, specimens should be collected 
at different times of the day. Our data for 
MEP and MEHHP suggest that this approach 
would maximize the suitability of the urinary 
concentrations of the various target biomark-
ers to reflect temporal exposure to nonper-
sistent chemicals. However, when and how 
often urine samples are collected will depend 
not only on how reproducible the urinary 
concentrations are (i.e., relatively high ICC), 
but also on the target population, aims of the 
study, major route of uptake of the parent 
phthalate, and excretion t1/2 of its metabolites. 
For DEP, sampling around midday on any 
given day may be advantageous if exposure 
occurs mainly through the use of personal 
care products and if these products are applied 
in the morning, because MEP excretion t1/2 is 
3–4 hr and peak excretion would be expected 
to occur around midday. Whether multiple 
sampling is needed for exposure assessment 
in specific situations (e.g., during pregnancy) 
will depend mainly on the intraperson vari-
ability at the sampling time (e.g., noon) and 
throughout the study period (e.g., 1 week). 
For DEHP, because of the strong influence 
of diet, the daily intraperson variability may 
be as high as the intraperson variability at one 
specific time of the day throughout the course 
of the study. When intraperson variability is 
unavoidable and highly independent of the 
sampling time, two potential approaches for 
conducting exposure assessment are as fol-
lows: a) use the mean or median urinary con-
centrations of all of the samples collected over 
a certain time period if multiple collections 
per person are possible, or b) if only one spot 
sample per person is available, use each indi-
vidual concentration and provide estimates 
of upper and lower confidence intervals (CIs) 
based on results from all participants. For 
the latter, our findings might serve as a basis 
for setting such fixed upper and lower CIs 
of exposure, in particular, for epidemiologic 
studies where recruitment of participants has 
been completed and multiple sampling for 
exposure assessment is no longer possible.
Among participants of NHANES 1999–
2000, variations have been reported in the dis-
tributions of urinary concentrations of MEP 
and other phthalate metabolites, depending 
on the time of day of sampling (Silva et al. 
2004). In addition to this variability, we found 
that MEP urinary concentrations also differed 
by age and race/ethnicity (Silva et al. 2004). 
Although the nature of the exposure to phtha-
lates and the short t1/2 of the phthalates will 
affect the urinary concentrations of phtha-
late metabolites on an individual basis, on a 
population basis, the range of concentrations 
observed in our study may represent an average 
exposure scenario. For example, MEP concen-
trations in the upper percentiles resulting from 
the collection of urine soon after DEP-related 
activity of an individual will likely be offset by 
a urinary concentration in the lower percen-
tiles originating from another person who pro-
vided a sample shortly before conducting the 
same activity. In this study, the considerable 
variation in concentrations of urinary biomark-
ers of DEP and DEHP suggests considerable 
variability in exposure among adults to these 
two phthalates selected to represent two main 
daily activities: use of personal care products 
(dermal exposure to DEP) and diet (inges-
tion exposure to DEHP). We hypothesize that 
the patterns of exposure variability observed 
for DEP and DEHP will encompass those of 
other phthalates such as dibutyl and benzyl-
butyl phthalates, which do not have a clearly 
identified predominant pathway of exposure 
for the average adult person. However, addi-
tional research is needed to assess the variability 
in exposure to other phthalates and among 
populations that encompass different lifestyles 
and life span stages.
Conclusions
When designing a biomonitoring study, one 
should consider the time of the sampling of 
the biological specimens (e.g., urine), particu-
larly for phthalates and other nonpersistent 
compounds with short elimination t1/2 (i.e., a 
few hours). Our data suggest that for DEHP 
and, by extension, other compounds to which 
people are exposed mostly through diet, col-
lecting 24-hr voids for only 1 day may not be 
advantageous for exposure assessment com-
pared with collecting spot urine samples. On 
the other hand, if multiple urine collections 
are taken over a period of time, changing the 
time of day of collection may provide the 
most complete approach for exposure assess-
ment, particularly when multiple phthalates 
and/or other compounds are evaluated, and 
thus minimize exposure misclassification. At 
the very least, we recommend that the time 
of day of urine collection and of the last 
urination be recorded. Despite the limita-
tions resulting from the temporality of the 
biomarkers of nonpersistent chemicals such 
as phthalates, relying on biomonitoring uri-
nary measures considerably strengthens the 
  exposure assessment.
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